Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan

National Taiwan University Hospital500 enrolled

Overview

To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.

To evaluate efficacy and safety profile of DC bead TACE in patients with hepatocellular carcinoma in Taiwan. This is a multi-center, retrospective, single arm study to explore safety and efficacy of DC bead TACE in hepatocellular carcinoma (HCC) in Taiwan Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7. All statistical data were analyzed with SPSS software (SPSS, IBM North America, New York, NY, USA). Demographic and baseline lab data are presented by using descriptive statistics Student's t-test. Survival analysis will includes all patients.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Hepatocellular Carcinoma Non-resectable Chemoembolization, Therapeutic

Interventions

Patient recordsDEVICE

Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a diagnosis of HCC, according to the AASLD diagnosis criteria for HCC. * Patient received DC bead TACE. Exclusion Criteria: * Patients with current any other cancer except non-melanomatous skin cancer. * Infiltrative HCC * Patients received ≥2 consecutive sessions of TACE (≥2 TACE at the same admission, no matter it is cTACE or DC bead TACE) * Patients received DC bead TACE and simultaneously received other therapy, such as radiotherapy, sorafenib etc. * Presence of collateral vessel pathways potentially endangering normal territories during embolization. * Presence of arteries supplying the lesion not large enough to accept DC Bead® microspheres.

Locations (1)

National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

Safety of the DC bead TACE

Safety of the DC bead TACE is evaluated based on the incidence of Grade 3 and Grade 4 toxicities up to 8 weeks following the procedure according to National Cancer Institute's Common Terminology Criteria for adverse events (CTCAE Version 4.03).

Time frame: One year.

Secondary Outcomes

Tumor response

Tumor response is assessed on triphase CT or contrast-enhanced MR study according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.

Time frame: One year.

Central Contacts

Chien-Hung Chen, MD

CONTACT

886-2-23123456 chenhcc@ntuh.gov.tw

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.